Clinical Trials · NCT03651765
Long Term Extension Trial of Setmelanotide
- Phase
- Phase 2/Phase 3
- Recruitment status
- Completed
- Sponsor
- Rhythm Pharmaceuticals, Inc.
- Enrollment
- 205
- Start date
- Jul 2018
- Locations
- 27 sites, 8 countries
- Primary endpoint
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)